Karyopharm Therapeutics Inc. (KPTI) — 8-K Filings

8-K Filings (27)

• Karyopharm Therapeutics Files 8-K — Mar 27, 2026 Risk: low
  Karyopharm Therapeutics Inc. filed an 8-K on March 27, 2026, to report other events. The filing does not contain specific financial figures or new material even
• Karyopharm Enters Material Agreement, Sells Unregistered Equity — Mar 24, 2026
  Karyopharm Therapeutics Inc. filed an 8-K on March 24, 2026, detailing an entry into a material definitive agreement and unregistered sales of equity securities
• Karyopharm Therapeutics Enters Material Definitive Agreement — Oct 14, 2025 Risk: medium
  Karyopharm Therapeutics Inc. announced on October 10, 2025, the entry into a material definitive agreement. This filing also indicates the creation of a direct
• Karyopharm Therapeutics Files 8-K with Material Agreements & Financial Updates — Oct 8, 2025 Risk: medium
  Karyopharm Therapeutics Inc. announced on October 7, 2025, the entry into a material definitive agreement. The company also reported on its results of operation
• Karyopharm Therapeutics Announces Executive and Board Changes — Sep 11, 2025 Risk: medium
  Karyopharm Therapeutics Inc. announced on September 5, 2025, changes in its executive team and board of directors. The filing details the departure of certain o
• Karyopharm Therapeutics Files 8-K — Jul 11, 2025 Risk: low
  Karyopharm Therapeutics Inc. filed an 8-K on July 11, 2025, reporting under Regulation FD and including financial statements and exhibits. The filing details th
• Karyopharm Therapeutics Reports Officer/Director Changes & Shareholder Votes — May 29, 2025 Risk: medium
  Karyopharm Therapeutics Inc. filed an 8-K on May 28, 2025, reporting on the departure of certain officers and directors, the election of new directors, and comp
• Karyopharm Therapeutics Files 8-K — Feb 24, 2025 Risk: medium
  Karyopharm Therapeutics Inc. filed an 8-K on February 24, 2025, reporting material modifications to the rights of security holders and amendments to its article
• Karyopharm Therapeutics Files 8-K on Financials — Feb 19, 2025 Risk: low
  Karyopharm Therapeutics Inc. filed an 8-K on February 19, 2025, reporting on its results of operations and financial condition. The filing includes financial st
• Karyopharm Therapeutics Announces Board and Executive Changes — Jan 31, 2025 Risk: medium
  Karyopharm Therapeutics Inc. announced on January 27, 2025, changes related to its board of directors and executive compensation. Specifically, the company repo
• Karyopharm Therapeutics Files 8-K on Security Holder Vote — Jan 30, 2025 Risk: low
  Karyopharm Therapeutics Inc. filed an 8-K on January 30, 2025, to report on the submission of matters to a vote of its security holders. The filing does not con
• Karyopharm Therapeutics Files 8-K on Financials — Jan 13, 2025 Risk: low
  Karyopharm Therapeutics Inc. filed an 8-K on January 13, 2025, reporting on its results of operations and financial condition. The filing includes financial sta
• Karyopharm Appoints Dr. Kolitz as Chief Medical Officer — Jan 2, 2025 Risk: low
  Karyopharm Therapeutics Inc. announced on January 2, 2025, the appointment of Dr. Jonathan G. Kolitz as Chief Medical Officer. Dr. Kolitz previously served as S
• Karyopharm Therapeutics Files 8-K — Dec 3, 2024 Risk: low
  Karyopharm Therapeutics Inc. filed an 8-K on December 3, 2024, to report a Regulation FD Disclosure and Financial Statements and Exhibits. The filing does not c
• Karyopharm Therapeutics Announces Executive and Board Changes — Nov 20, 2024 Risk: medium
  Karyopharm Therapeutics Inc. announced on November 20, 2024, changes in its executive team and board of directors. Dr. John G. Simon has been appointed as the n
• Karyopharm Therapeutics Enters Material Definitive Agreement — Nov 8, 2024 Risk: medium
  Karyopharm Therapeutics Inc. announced on November 5, 2024, that it entered into a Material Definitive Agreement. The filing does not provide specific details a
• Karyopharm Therapeutics Files 8-K on Financials — Nov 5, 2024 Risk: low
  Karyopharm Therapeutics Inc. filed an 8-K on November 5, 2024, reporting on its results of operations and financial condition. The filing details financial stat
• Karyopharm Therapeutics Files 8-K — Oct 31, 2024 Risk: low
  Karyopharm Therapeutics Inc. filed an 8-K on October 31, 2024, to report on various corporate events. The filing includes information related to financial state
• Karyopharm Therapeutics Faces Delisting Notice — Sep 17, 2024 Risk: high
  Karyopharm Therapeutics Inc. filed an 8-K on September 17, 2024, reporting a notice of delisting or failure to meet continued listing standards as of September
• Karyopharm Appoints New Chief Medical Officer — Aug 29, 2024 Risk: low
  Karyopharm Therapeutics Inc. announced on August 26, 2024, the appointment of Dr. John J. O'Malley as Chief Medical Officer, effective immediately. Dr. O'Malley
• Karyopharm Therapeutics Files 8-K on Financials — Aug 6, 2024 Risk: low
  Karyopharm Therapeutics Inc. filed an 8-K on August 6, 2024, reporting on its results of operations and financial condition. The filing details information abou
• Karyopharm Therapeutics Announces Board Changes and New CMO — May 31, 2024 Risk: medium
  Karyopharm Therapeutics Inc. announced on May 29, 2024, a series of corporate actions including the departure of Director Michael W. Yothers, the election of ne
• Karyopharm Therapeutics to be Acquired for $1 Billion — May 14, 2024 Risk: medium
  Karyopharm Therapeutics Inc. announced on May 13, 2024, that it has entered into a definitive agreement to be acquired by an affiliate of HealthCare Royalty Par
• Karyopharm Therapeutics Files 8-K — May 8, 2024 Risk: low
  Karyopharm Therapeutics Inc. filed an 8-K on May 8, 2024, reporting on its results of operations and financial condition, as well as financial statements and ex
• Karyopharm Therapeutics Files 8-K on Financial Condition — Feb 29, 2024 Risk: low
  Karyopharm Therapeutics Inc. filed an 8-K on February 29, 2024, to report on its results of operations and financial condition. The filing, under SEC File Numbe
• Karyopharm Therapeutics Files 8-K on Feb 16 Event — Feb 20, 2024 Risk: low
  Karyopharm Therapeutics Inc. filed an 8-K on February 20, 2024, reporting an event that occurred on February 16, 2024. The filing is a 'Current Report' under Se
• Karyopharm Therapeutics Files 8-K on Financial Condition — Jan 8, 2024
  Karyopharm Therapeutics Inc. filed an 8-K on January 8, 2024, to report on its 'Results of Operations and Financial Condition' and 'Financial Statements and Exh

Popular Companies

AAPL · TSLA · MSFT · AMZN · GOOGL · META · NVDA · JPM · BRK-B · V · JNJ · UNH · XOM · WMT · MA · PG · HD · DIS · BAC · NFLX